Latest News-Ascletis Pharma Inc. Mediaroom_Page

China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne

HANGZHOU and SHAOXING, China, Aug. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) t...

2021-08-09 08:30 3083

Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analo...

2021-07-28 08:30 2575

China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma

HANGZHOU, China and SHAOXING, China, July 22, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2021-07-22 08:30 2724

Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China

--This bridging study to select doses for the Phase II trial in China in patients with chronic hep...

2021-07-13 08:30 2815

Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist

SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-06-16 21:00 3158

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)...

2021-06-07 08:30 3093

Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication

SHANGHAI, May 27, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX...

2021-05-27 08:30 2944

Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA

HANGZHOU and SHAOXING, China, May 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) t...

2021-05-25 08:30 2792

Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

HANGZHOU and SHAOXING, China, May 5, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) toda...

2021-05-05 08:30 3095

Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41

SHANGHAI, April 14, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HK...

2021-04-14 20:00 3502

Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021

HANGZHOU, China and SHAOXING, China, April 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...

2021-04-12 08:30 3457

Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

* Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chi...

2021-03-30 08:00 4004

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH

* Oral FASN inhibitor ASC40 shown to meaningfully reduce liver fat with a 50% responder rate * ...

2021-03-09 08:30 7359

Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH

SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-02-25 08:30 3070

Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41

SHANGHAI, Feb. 21, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-02-21 19:30 3877

Ascletis Joins Sagimet's US$80 Million in Crossover Financing with Premium Investors

HANGZHOU, China and SHAOXING, China, Feb. 11, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2021-02-11 22:30 10815

Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41

SHANGHAI, Jan. 11, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-01-12 08:30 2364

First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial

SHANGHAI, Dec. 28, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-12-28 08:30 3886

Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

SHANGHAI, Dec. 22, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-12-22 19:18 3096

Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-12-14 08:30 2895